Idexx Laboratories Inc (IDXX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Idexx Laboratories Inc (IDXX)
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
Key Insights
Critical company metrics and information
Share Price
$431.83Market Cap
$35.36 BillionTotal Outstanding Shares
81.89 Million SharesTotal Employees
11,000Dividend
No dividendIPO Date
June 21, 1991SIC Description
In Vitro & In Vivo Diagnostic SubstancesHomepage
https://www.idexx.com
Historical Stock Splits
If you bought 1 share of IDXX before November 27, 2007, you'd have 4 shares today.
| Execution Date | Split Amount |
|---|---|
| June 16, 2015 | 2-for-1 |
| November 27, 2007 | 2-for-1 |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities, Continuing | $-197.65 Million |
| Exchange Gains/Losses | $4.90 Million |
| Net Cash Flow From Operating Activities | $916.83 Million |
| Net Cash Flow | $-23.06 Million |
| Net Cash Flow From Financing Activities | $-747.13 Million |
| Net Cash Flow From Investing Activities | $-197.65 Million |
| Net Cash Flow From Financing Activities, Continuing | $-747.13 Million |
| Net Cash Flow From Operating Activities, Continuing | $916.83 Million |
| Net Cash Flow, Continuing | $-27.96 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Basic Earnings Per Share | $10.46 |
| Income/Loss From Continuing Operations Before Tax | $1.09 Billion |
| Cost Of Revenue | $1.51 Billion |
| Net Income/Loss Attributable To Parent | $866.24 Million |
| Research and Development | $213.88 Million |
| Income Tax Expense/Benefit | $226.87 Million |
| Operating Income/Loss | $1.11 Billion |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Income/Loss From Continuing Operations After Tax | $866.24 Million |
| Revenues | $3.84 Billion |
| Provision For Loan, Lease, And Other Losses | $5.17 Million |
| Costs And Expenses | $2.75 Billion |
| Diluted Earnings Per Share | $10.36 |
| Operating Expenses | $1.22 Billion |
| Benefits Costs and Expenses | $2.75 Billion |
| Basic Average Shares | $82.68 Million |
| Gross Profit | $2.33 Billion |
| Income Tax Expense/Benefit, Deferred | $-62.43 Million |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Net Income/Loss | $866.24 Million |
| Diluted Average Shares | $83.47 Million |
| Other Operating Expenses | $1.01 Billion |
| Net Income/Loss Available To Common Stockholders, Basic | $866.24 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Inventory | $389.80 Million |
| Current Liabilities | $1.01 Billion |
| Prepaid Expenses | $57.22 Million |
| Other Current Assets | $986.72 Million |
| Other Non-current Assets | $1.09 Billion |
| Current Assets | $1.43 Billion |
| Noncurrent Liabilities | $723.49 Million |
| Fixed Assets | $717.75 Million |
| Equity | $1.62 Billion |
| Liabilities And Equity | $3.35 Billion |
| Assets | $3.35 Billion |
| Other Current Liabilities | $739.64 Million |
| Intangible Assets | $106.89 Million |
| Liabilities | $1.73 Billion |
| Noncurrent Assets | $1.92 Billion |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Wages | $158.99 Million |
| Accounts Payable | $110.60 Million |
| Equity Attributable To Parent | $1.62 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Related Companies
View additional S&P 500 companies similar to Idexx Laboratories Inc (IDXX)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.